1.2-mg cagrilintide: 15.7% drop in body weight from baseline
2.4-mg cagrilintide: 17.1% drop
4.5-mg cagrilintide: 15.4% drop
In comparison with placebo plus semaglutide, 1.2 mg, 2.4 mg, and 4.5 mg of cagrilintide plus semaglutide all resulted in significantly greater estimated treatment differences for change in baseline body weight.
Doses of 0.16 mg (8.3% drop in baseline body weight), 0.30 mg (10% drop), and 0.60 mg (10.6% drop) of cagrilintide plus 2.4-mg semaglutide all yielded slightly greater drops in baseline body weight versus placebo plus semaglutide, although the differences weren't statistically significantly.
Across the board, glycemic parameters showed improvement in all treatment groups regardless of the cagrilintide dose.
These findings built upon a previous phase II monotherapy trial, initially presented at the 2020 virtual ObesityWeek, which met its primary endpoint showing a 10.8% weight loss at week 26 with 4.5-mg cagrilintide compared with a 3% weight loss with placebo.